Organosilicon-heparin composite membrane as well as preparation method and application thereof
The organosilicon-heparin composite membrane, which combines organosilicon with a porous basement membrane, solves the problems of insufficient permeability, selectivity and anticoagulation of oxygenation membrane materials, and achieves high blood compatibility and anticoagulation effect, making it suitable for artificial lung applications.
Patent Information
- Application Number
- CN202511764125.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-11-27
- Publication Date
- 2026-03-06
Smart Images
Figure CN121606741A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical materials technology, specifically relating to an organosilicon-heparin composite membrane, its preparation method, and its application. Background Technology
[0002] Extracorporeal membrane oxygenation (ECMO) is an important treatment for critically ill patients with acute respiratory distress syndrome (ARDS). The oxygenation membrane, as the core component of the oxygenator, acts as a substitute for the alveoli in the exchange of blood and gases. Therefore, a high-performance oxygenation membrane needs to have high permeability and CO2 / O2 selectivity, as well as blood compatibility and resistance to plasma leakage.
[0003] Polydimethylsiloxane (PDMS) materials possess excellent permeability, blood compatibility, leak resistance, and chemical resistance, but lack mechanical strength. When using PDMS materials for artificial lung membranes, the manufacturing thickness must exceed 100 µm to withstand pressure, but this results in an effective oxygen permeability of only 10 GPU. Polypropylene (PP) microporous membranes are susceptible to plasma leakage, thus affecting gas permeation and exchange. Poly(4-methyl-1-pentene) (PMP) faces difficulties in membrane fabrication due to the density difference between irregular crystalline and amorphous regions, and raw material supply is limited.
[0004] Meanwhile, thrombosis often occurs during extracorporeal blood circulation, especially with hydrophobic membranes like these. The turbulent flow of the patient's blood makes it easier to induce plasma protein adsorption and platelet adhesion, further activating the coagulation pathway. Although injectable anticoagulants and heparinized circulation modules are widely used to achieve systemic anticoagulation, the administration of these anticoagulants may lead to the indivisible inactivation of coagulation factors, resulting in abnormal hemostasis and even severe postoperative bleeding. Furthermore, the currently used PP and PMP surfaces lack active groups, requiring plasma to load heparin anticoagulant materials, which can result in insufficient grafting or reactant residue, affecting the anticoagulant effect.
[0005] To better adapt to applications involving direct contact with large amounts of blood, it is extremely important to further select active membrane materials and combine them with heparin to improve the membrane's anticoagulation performance, while ensuring that the artificial lung membrane has excellent CO2 / O2 selectivity. Summary of the Invention
[0006] Purpose of the invention: To address the shortcomings of existing technologies, this invention provides an organosilicon-heparin composite membrane, its preparation method, and its applications.
[0007] This invention employs an organosiloxane for preparing organosilicone membranes. After hydrolysis, each Si group in this organosilicone material can connect to three reactive hydrophilic groups. While polymerizing to form a membrane, it can also bond to a porous membrane substrate and heparin material, forming an organosilicone-heparin composite membrane. This overcomes the limitations of existing materials due to their inertness, making it difficult to graft anticoagulant materials, thus improving anticoagulation time. In addition to the three active groups, the Si group also connects to a hydrophobic alkyl group, preventing plasma leakage in the blood. The resulting network structure gives the membrane high CO2 permeability and CO2 / O2 selectivity. Therefore, the organosilicone-heparin composite membrane provided by this invention exhibits excellent blood compatibility, permeability, and selectivity.
[0008] Technical solution: The objective of this invention is achieved through the following technical solution: This invention provides a method for preparing an organosilicon-heparin composite membrane, comprising the following steps: (1) An organosilicon sol containing active groups was prepared by adding solvent, water and catalyst to the organosilicon source precursor; (2) The organosilicon sol obtained in step (1) is loaded onto a porous substrate membrane material by a scraping method, and then calcined to obtain an organosilicon membrane layer. (3) The organosilicon film layer obtained in step (2) is immersed in a solution containing heparin material and polymerized by heating to obtain the organosilicon-heparin composite film; The organosilicon source precursor is selected from 1,2-bis(triethoxysilyl)ethane or 1,8-bis(triethoxysilyl)octane; The porous base membrane material is polypropylene (PP) or polyethersulfone (PES).
[0009] The present invention relates to an organosilicon-heparin composite membrane, which is composed of an organosilicon membrane layer and an anticoagulant membrane layer; the anticoagulant membrane layer is prepared by immersing the organosilicon membrane layer in a solution containing anticoagulant material by an impregnation method; the organosilicon membrane layer is prepared on a porous base membrane material by a blade coating method.
[0010] The organosilicon film of the present invention is prepared by hydrolyzing the active groups in an organosilicon source precursor containing hydrolyzable groups to generate silanol groups, and then partially polymerizing the silanol groups on a porous substrate membrane material to obtain an organosilicon film containing both hydrophilic hydroxyl groups and hydrophobic alkyl groups.
[0011] Preferably, in step (1), the solvent is anhydrous ethanol or isopropanol; the molar ratio of the organosilicon source precursor, water and catalyst is 1:6-120:0.1; and the mass fraction of the organosilicon source precursor in the reaction system is maintained at 3-10 wt%.
[0012] More preferably, the solvent is anhydrous ethanol; the molar ratio of the organosilicon source precursor, water and catalyst is 1:6-60:0.1; and the mass fraction of the organosilicon source precursor in the reaction system is maintained at 3-5 wt%.
[0013] Preferably, the porous base membrane material is polypropylene (PP).
[0014] Preferably, in step (2), the coating method involves pouring the organosilicon sol obtained in step (1) onto a porous substrate membrane material and coating the membrane with a 4µm blade at a speed of 1-3 s / cm.
[0015] Preferably, in step (2), the roasting temperature is 100-200℃ and the roasting time is 30-60 minutes. The roasting process of the present invention can be carried out in an air atmosphere.
[0016] Preferably, in step (2), the coating and baking processes are repeated 2-5 times to form a defect-free silicone film.
[0017] A further preferred embodiment of the present invention is to coat the organosilicon sol obtained in step (1) onto a porous substrate membrane material and bake it in an air atmosphere at 100-150°C for 30-40 minutes. The coating and baking process is repeated 2-3 times to form the organosilicon membrane.
[0018] Preferably, in step (3), the concentration of heparin-containing material in the solution is 10-50 mg / mL.
[0019] Furthermore, the concentration of heparin-containing material in the solution is 10-20 mg / mL.
[0020] A further preferred embodiment of the present invention is to dissolve 1g of heparin sodium salt in 50-100mL of buffer PBS or MES to prepare an anticoagulant solution with a concentration of 10-20mg / mL.
[0021] Preferably, in step (3), the immersion time is 4-24 hours.
[0022] More preferably, the immersion time is 4-8 hours.
[0023] Preferably, in step (3), the heating polymerization temperature is 80-120℃ and the time is 30-60min.
[0024] A further preferred embodiment of the present invention is to immerse the organosilicon film in an anticoagulant solution containing 10 mg / mL heparin for 4 hours, and then heat it at 90-100°C for 60 minutes to polymerize it.
[0025] The present invention also provides an organosilicon-heparin composite membrane prepared by the above preparation method.
[0026] The present invention also provides the application of the above-mentioned organosilicon-heparin composite membrane in the preparation of blood-related biomedical materials, which are used in artificial lungs. Beneficial effects
[0027] This invention uses a hydrolysis catalysis method to form a polyhydroxy organosilicon sol, which is then coated onto a substrate material by a blade coating method and heated. After heating, some hydroxyl groups undergo self-condensation and bond with the substrate to form a polymer film. Furthermore, the remaining silanol groups react with the active groups of the anticoagulant material to form a covalent bond, thus preparing an organosilicon polymer-anticoagulant composite film.
[0028] The organosilicon-heparin composite membrane prepared by this invention reduces the adsorption and interaction of various components in the blood on the material surface, effectively improving the blood compatibility and anticoagulation time of the coated material. At the same time, it has high CO2 permeability and CO2 / O2 selectivity, and can be used in biomedical materials such as artificial lungs. Attached Figure Description
[0029] Figure 1 Water contact angle diagrams of the PP membrane of Comparative Example 1, the PDMS membrane layer and PDMS-Hep membrane layer of Comparative Example 2, and the BTESE membrane layer and BTESE-Hep composite membrane layer of Example 1. Figure 2 The APTT test results are for the PP membrane of Comparative Example 1, the PDMS membrane layer and PDMDS-Hep membrane layer of Comparative Example 2, and the BTESE membrane layer and BTESE-heparin membrane layer of Example 1. Figure 3 The 3000× SEM images show the erythrocyte adhesion of the PDMS membrane, PDMS-heparin membrane, and BTESE membrane and BTESE-Hep composite membrane of Comparative Example 2. Detailed Implementation
[0030] The technical solution of the present invention will be described in detail below through specific embodiments, but the scope of protection of the present invention is not limited to the embodiments described.
[0031] Where specific techniques or conditions are not specified in the examples, they shall be performed in accordance with the techniques or conditions described in the literature in this field, or in accordance with the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased through legitimate channels.
[0032] Unless otherwise specified, the experimental methods used in the following examples are conventional methods. Unless otherwise specified, the experimental materials used in the following examples are commercially available products.
[0033] The performance of the organosilicon membrane and organosilicon-heparin composite membrane prepared by the present invention was tested by contacting the membrane with blood to test the hemolysis rate, red blood cell adhesion, activated partial thromboplastin time (APTT) and CO2 / O2 selectivity.
[0034] The testing method is as follows.
[0035] I. Hemolysis rate test 1. Cut a 1cm round piece of composite membrane, place it in a test tube and add 10mL of physiological saline, and incubate in a 37℃ water bath for 30min; 2. Take 4 mL of whole blood (purchased from Nanjing Quanlong Biotechnology Co., Ltd., rabbit blood) and dilute it in 5 mL of physiological saline. Take 0.2 mL of the diluted blood and add it to the incubated test tubes, then incubate in a 37℃ water bath for 1 hour; 3. Remove the test tube and centrifuge at 1000 r / min. After centrifugation, take the supernatant and measure the absorbance at 540 nm using a spectrophotometer. Set up three parallel samples for each group. 4. The negative control group consisted of 10 mL of physiological saline and 0.2 mL of diluted blood, while the positive control group consisted of 10 mL of pure water and 0.2 mL of diluted blood. The mixtures were incubated at 37°C for 1 hour.
[0036] Hemolysis rate (%) = (sample absorbance value - negative control absorbance value) / (positive control absorbance value - negative control absorbance value) × 100%.
[0037] II. Erythrocyte adhesion 1. Take 10 mL of whole blood (rabbit blood from Nanjing Quanlong Biotechnology Co., Ltd.) and centrifuge at 3000 r / min for 20 min at 4℃. Remove the supernatant and the lower layer is red blood cells. 2. Add an equal volume of PBS solution to the red blood cells, centrifuge at 3000 r / min for 5 min, remove the supernatant, and wash at least three times until the supernatant is clear; 3. Take the lower layer of red blood cells and add them to PBS solution to prepare a 4v / v% red blood cell suspension; 4. Place the composite membrane into a 24-well plate, add 1 mL of red blood cell suspension to each well, and incubate at 37°C for 2 hours; 5. Remove the membrane disc, rinse off any loosely adhered red blood cells with PBS, and immerse it in glutaraldehyde electron microscopy fixative overnight at 4°C. 6. Remove the film disc and immerse it sequentially in 30%, 50%, 70%, 90%, and 100% ethanol aqueous solutions for 15 minutes each for gradient dehydration. Freeze-dry the sample, sputter gold onto the sample surface, and take SEM images.
[0038] III. Activated Partial Thromboplastin Time (APTT) 1. Take 20 mL of whole blood (rabbit blood from Nanjing Quanlong Biotechnology Co., Ltd.) and centrifuge at 3000 r / min for 20 min at 4℃. Take the supernatant as anemic platelet plasma (PPP). 2. Preheat the 0.025 mol / L CaCl2 solution to 37°C, and remove the APTT reagent from the refrigerator to room temperature; 3. Place the composite membrane into a 24-well plate, add 150 μL of PPP to each membrane disc, and incubate in a water bath at 37°C for 30 min; 4. Take 50 μL of the incubated PPP and put it into the coagulation cup of the coagulation analyzer. Add 50 μL of APTT reagent and mix for 1 min. Then add 50 μL of CaCl2 solution to activate coagulation. 5. Record the blood coagulation analyzer reading as the activated partial thromboplastin time (PPP). Measure PPP twice on each membrane disc and three sets of measurements for each sample.
[0039] IV. CO2 / O2 Selectivity Gas testing experiments on the organosilicon composite membrane were conducted using the constant pressure variable volume method (reference: Separation and Pµrification Technology, 2025, 358, 130419). Permeation experiments were performed after the system reached stability. All tests were repeated at least three times. The permeability of component i can be calculated using the following formula:
[0040] P in the formula i Gas permeability of component i (1 GPU = 10) -6 cm 3 (STP) cm -2 s -1 cmHg), Q i It is the volume change of component i (cm) -2 s -1 (STP), where Δp represents the pressure difference (cmHg) across the sample cell, and A is the effective membrane area. The ideal selectivity of the membrane is calculated as the ratio of CO2 permeability to O2 permeability:
[0041] The PP membrane, PES membrane, and polyvinylidene fluoride membrane used in the embodiments and comparative examples of this invention, with a pore size of 0.1µm and a diameter of 30mm, were purchased from Haining Delu New Material Technology Co., Ltd.
[0042] Example 1 Preparation of a composite membrane of 1,2-bis(triethoxysilyl)ethane (BTESE) organosilicon and heparin (1) Preparation of organosilicon sol: 1.0 g of BTESE was dissolved in 15.67 g of anhydrous ethanol, and then 3.05 g of water and 0.28 g of hydrochloric acid with a mass fraction of 3.7 wt% (molar ratio of BTESE:H2O:HCl = 1:60:0.1) were added. The mixture was stirred for 2 h to prepare organosilicon sol containing multiple active groups, wherein the mass fraction of BTESE was 5 wt%.
[0043] (2) Preparation of silicone film: Silicone sol was prepared on PP film by scraping. The scraper was 4µm and the speed was 2s / cm. After drying at room temperature, it was calcined at 110℃ for 30min. The coating and calcination process was repeated 3 times to obtain a uniform silicone film.
[0044] (3) Preparation of organosilicon-heparin composite membrane: Dissolve 200 mg of heparin sodium salt (Hep) in 20 ml of PBS buffer to prepare a 10 mg / mL heparin sodium solution. Immerse the organosilicon membrane in the heparin sodium solution for adsorption for 6 h, and heat it in a 90 °C oven for 60 min to obtain the organosilicon-heparin composite membrane.
[0045] The prepared organosilicon film was characterized by contact angle and microscopy, with the water contact angle of BTESE as shown in the figure. Figure 1 The value shown is 65.5. o Between 0 and 90 o Further APTT anticoagulation time tests were conducted on the BTESE membrane, such as... Figure 2 As shown, it is 25s.
[0046] The contact angle of the prepared organosilicon-heparin (BTESE-Hep) composite membrane was tested, such as... Figure 1 As shown, it is 36.2. o Increased hydrophilicity improves blood compatibility. The test results obtained through coagulation performance evaluation are as follows: Figure 2 As shown, the APTT anticoagulation time was >180s; further blood compatibility testing showed that the hemolysis rate was 0.55%, which is <5% of the national standard (GB / T16886.4-2017). The prepared BTESE-Hep composite membrane was subjected to CO2 / O2 permeation test. The results showed that the CO2 permeation rate was 3200 GPU and the CO2 / O2 selectivity was around 9.
[0047] Example 2 Preparation of a composite membrane of 1,8-bis(triethoxysilyl)octane (BTESO) organosilicon and heparin (1) Preparation of organosilicon sol: 1.0 g of BTESO was dissolved in 16.23 g of anhydrous ethanol, and then 2.54 g of water and 0.23 g of hydrochloric acid with a mass fraction of 3.7 wt% were added (molar ratio BTESO:H2O:HCl = 1:60:0.1). After stirring for 2 h, organosilicon sol containing multiple active groups was prepared, wherein the mass fraction of BTESO was 5 wt%.
[0048] Steps (2) and (3) are the same as in Example 1.
[0049] The coagulation performance of the prepared BTESO organosilicon-heparin (BTESO-Hep) composite membrane was evaluated, and the APTT anticoagulation time was >180s. Further blood compatibility testing showed that the hemolysis rate was 0.85%, which is <5% of the national standard (GB / T16886.4-2017). The prepared BTESO-Hep composite membrane was subjected to CO2 / O2 permeation test. The results showed that the CO2 permeation rate was 2600 GPU and the CO2 / O2 selectivity was around 5.
[0050] Example 3 Preparation of a composite membrane of 1,2-bis(triethoxysilyl)ethane (BTESE) organosilicon and heparin (1) Preparation of organosilicon sol: 1,2-bis(triethoxysilyl)ethane (BTESE) was used as the organosilicon precursor. 1.0 g of BTESE was dissolved in 23.87 g of anhydrous ethanol, and then 6.10 g of water and 0.28 g of hydrochloric acid with a mass fraction of 3.7 wt% (molar ratio BTESE:H2O:HCl = 1:120:0.1) were added. The mixture was stirred for 2 h to prepare an organosilicon sol containing multiple active groups, wherein the mass fraction of BTESE was 3.2 wt%.
[0051] (2) Preparation of silicone film: Silicone sol was prepared on PES film by scraping with a scraper of 4µm and a speed of 1s / cm. After drying at room temperature, it was calcined at 200℃ for 30min. The coating and calcination process was repeated 3 times to obtain a uniform silicone film.
[0052] (3) Preparation of organosilicon-heparin composite membrane: Dissolve 400 mg of heparin sodium salt (Hep) in 20 ml of PBS buffer to prepare a 20 mg / mL heparin sodium solution. Immerse the organosilicon membrane in the heparin sodium solution for adsorption for 4 h, and heat and polymerize it in a 100 °C oven for 60 min to obtain the organosilicon-heparin composite membrane.
[0053] The coagulation performance of the prepared organosilicon-heparin (BTESE-Hep) composite membrane was evaluated, and the APTT anticoagulation time was >180s. Further blood compatibility testing showed that the hemolysis rate was 0.70%, which is <5% of the national standard (GB / T16886.4-2017). The prepared BTESE-Hep composite membrane was subjected to CO2 / O2 permeation test. The results showed that the CO2 permeation rate was 2800 GPU and the CO2 / O2 selectivity was around 11.
[0054] Example 4 Preparation of a composite membrane of 1,8-bis(triethoxysilyl)octane (BTESO) organosilicon and heparin (1) Preparation of organosilicon sol: 1.0 g of BTESO was dissolved in 8.52 g of anhydrous ethanol, and then 0.25 g of water and 0.23 g of hydrochloric acid with a mass fraction of 3.7 wt% (molar ratio BTESO:H2O:HCl=1:6:0.1) were added. After stirring for 2 h, organosilicon sol containing multiple active groups was prepared, wherein the mass fraction of BTESO was 10 wt%.
[0055] (2) Preparation of silicone film: Silicone sol was prepared on PES film by scraping. The scraper was 4µm and the speed was 3s / cm. After drying at room temperature, it was calcined at 150℃ for 60min. The coating and calcination process was repeated 3 times to obtain a uniform silicone film.
[0056] (3) Preparation of organosilicon-heparin composite membrane: Dissolve 400 mg of heparin sodium salt (Hep) in 20 ml of PBS buffer to prepare a 20 mg / mL heparin sodium solution. Immerse the organosilicon membrane in the heparin sodium solution for 24 h for adsorption, and then heat and polymerize it in a 90 °C oven for 60 min to obtain the organosilicon-heparin composite membrane.
[0057] The coagulation performance of the prepared organosilicon-heparin (BTESO-Hep) composite membrane was evaluated, and the APTT anticoagulation time was >180s. Further blood compatibility testing showed that the hemolysis rate was 2.25%, which is <5% of the national standard (GB / T16886.4-2017). The prepared BTESO-Hep composite membrane was subjected to CO2 / O2 permeation test. The results showed that the CO2 permeation rate was 1100 GPU and the CO2 / O2 selectivity was around 4.
[0058] Comparative Example 1 Using polypropylene (PP) film as a blank control, contact angle tests were performed on it, such as... Figure 1 The value shown is 111.0. o It is hydrophobic; APTT anticoagulation time is as follows Figure 2The result is shown as 25 seconds. Further blood compatibility testing revealed a hemolysis rate of 1.7%. CO2 / O2 permeability testing of the PP membrane yielded the following results: CO2 permeability was 29000 GPU, and CO2 / O2 selectivity was 1.2.
[0059] Comparative Example 2 Polydimethoxysilane PDMS film was used as a control for contact angle, hemolysis and protein adhesion, APTT anticoagulation test and gas test.
[0060] Preparation of PDMS film: PDMS (Dow Corning) from DC184 was dissolved in ethanol to form a 5wt% PDMS solution. Then, 50 mL of the PDMS solution was poured onto a PP membrane and coated using a 4µm blade at a speed of 2 s / cm. After drying at room temperature, the membrane was calcined at 110℃ for 30 min. This coating and calcination process was repeated three times to obtain the PDMS film.
[0061] Preparation of PDMS-Hep composite membrane: Dissolve 200 mg of heparin sodium salt (Hep) in 20 ml of PBS buffer to prepare a 10 mg / mL heparin sodium solution. Immerse the organosilicon membrane in the heparin sodium solution for adsorption for 6 h, place it in a 90 °C oven for heating for 60 min, and dry to obtain the PDMS-heparin composite membrane.
[0062] The contact angle of the prepared PDMS membrane was tested, and the water contact angle of the PDMS was as follows: Figure 1 The value shown is 104.4. o It has hydrophobic properties; APTT anticoagulation time is as follows Figure 2 The value shown is 25 seconds.
[0063] The water contact angle of the prepared PDMS-Hep composite membrane was tested, such as... Figure 1 As shown, it is 100.5. o Compared to unheparinized PDMS, the change in water contact was smaller, indicating that less heparin was grafted onto the hydrophobic PDMS. The coagulation performance assessment results are as follows: Figure 2 As shown, the APTT anticoagulation time did not change significantly and remained at 25s; further blood compatibility testing of the membrane layer showed a hemolysis rate of 1%.
[0064] The CO2 / O2 permeation test was performed on the prepared PDMS-Hep composite membrane. The results showed that the CO2 permeation rate was 180 GPU and the CO2 / O2 selectivity was about 1.5.
[0065] Comparative Example 3 The preparation method is the same as in Example 1, except that the porous substrate used is a polyvinylidene fluoride membrane, and an organosilicon-heparin composite membrane is prepared.
[0066] The coagulation performance of the prepared organosilicon-heparin composite membrane was evaluated, and the APTT anticoagulation time was 15s. Further blood compatibility tests were conducted on the membrane layer, and the hemolysis rate was 4.5%.
[0067] The prepared composite membrane was subjected to a CO2 / O2 permeation test. The results showed that the CO2 permeation rate was 400 GPU and the CO2 / O2 selectivity was approximately 2.1.
[0068] Red blood cell adhesion tests were performed on the membranes of Example 1 and Comparative Example 2 before and after heparin grafting, as shown in the results. Figure 3 As shown, erythrocyte adhesion was high before and after PDMS grafting, while erythrocyte adhesion was significantly reduced in the organosilicon membrane. After heparin grafting, there was almost no adhesion on the surface, and the membrane remained intact. This indicates that the organosilicon membrane significantly improved the anti-erythrocyte adhesion performance of the porous basement membrane material, and the reduced erythrocyte adhesion effectively alleviated coagulation. The APTT also showed that the anticoagulation time of organosilicon-heparin was significantly prolonged, indicating that the organosilicon-heparin composite membrane further enhanced the anticoagulation performance of blood, which is beneficial for contact with blood in the artificial lung.
[0069] As described above, although the invention has been shown and described with reference to specific preferred embodiments, it should not be construed as limiting the invention itself. Various changes in form and detail may be made without departing from the spirit and scope of the invention as defined in the appended claims.
Claims
1. A method for producing a silicone-heparin composite film, characterized by, The method comprises the following steps: (1) adding an organic silicon source precursor into a solvent, water and a catalyst to prepare an organic silicon sol containing active groups; (2) loading the organic silicon sol prepared in step (1) on a porous substrate film material by a doctor blade method, and baking to prepare an organic silicon film layer; (3) immersing the organic silicon film layer prepared in step (2) into a solution containing heparin material, and polymerizing by heating to obtain the organic silicon-heparin composite film; The organic silicon source precursor is selected from 1,2-bis(triethoxysilyl)ethane or 1,8-bis(triethoxysilyl)octane. The porous substrate film material is polypropylene (PP) or polyether sulfone (PES).
2. The production method according to claim 1, characterized by, In step (1), the solvent is anhydrous ethanol or isopropanol; the molar ratio of the organic silicon source precursor, water and the catalyst is 1:6-120:0.1; and the mass fraction of the organic silicon source precursor in the reaction system is kept at 3-10wt%.
3. The preparation method according to claim 1, characterized in that, In step (2), the doctor blade method is to pour the organic silicon sol prepared in step (1) on the porous substrate film material, and to coat the film by using a 4µm doctor blade at a speed of 1-3s / cm.
4. The method of claim 1, wherein, In step (2), the baking temperature is 100-200℃, and the baking time is 30-60min.
5. The preparation method according to claim 1, characterized in that, In step (2), the coating and baking process is repeated for 2-5 times to form a defect-free organic silicon film layer.
6. The method of claim 1, wherein, In step (3), the concentration of the heparin material in the solution is 10-50mg / mL.
7. The preparation method according to claim 1, characterized in that, In step (3), the immersion time is 4-24h.
8. The method of claim 1, wherein, In step (3), the heating polymerization temperature is 80-120℃, and the time is 30-60min.
9. An organic silicon-heparin composite film prepared by the preparation method of any one of claims 1-8.
10. Use of the silicone-heparin composite film according to claim 9 for the production of a biomedical material related to blood, characterized in that, The biomedical material is used in an artificial lung.